---
title: Adeno or Other in Stage IV NSCLC Treatment
---
# Adeno or Other in Stage IV NSCLC Treatment

| Genetics                 | %    | Treatment                                                                                                      |
| ------                   | ---- | ----------------------                                                                                         |
| [[EGFR]]                     | ~15  | 1st line: osimertinib if L858R, ex19del (NEJM 2018;378:113)                                                    |
| [[EGFR ex20 insertion]]      | 2–3  | Subsequent Rx w/ amivantamab (JCO 2021;39:3391) or mobocertinib (JAMA Onc 2021;7:e214761) after platinum chemo |
| ALK                      | ~4   | 1st line: alectinib pref. b/c CNS activity (NEJM 2017;377:829)                                                 |
| ROS1                     | 2    | Crizotinib pref. (JCO 2017;35:2613); entrectinib (Lancet Onc 2020;21:261)                                      |
| MET ex14 skip or amplif. | 3    | Capmatinib (NEJM 2020;383:944) or tepotinib (NEJM 2020;383:931)                                                |
| RET                      | 1    | Selpercatinib (NEJM 2020;383:813) or pralsetinib (Lancet Onc 2021;22: 959-969)                                 |
| BRAF V600E               | 1–3  | Dabrafenib + trametinib (Lancet Onc 2016;17:984)                                                               |
| NTRK fusions             | <1   | Larotrectinib (NEJM 2018;378:731)                                                                              |
| KRAS G12C                | ~13  | Subsequent Rx w/ sotorasib (NEJM 2021;384:2371)                                                                |
| PD-L1≥50%                | 30   | Pembrolizumab or chemo + pembro (NEJM 2018;378:2078)                                                           |

No targets & PD-L1 <50% :
* Chemo (carbo/pemetrexed) + pembro (NEJM 2018;378:2078)
[[Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer]]

* carbo/paclitaxel + anti-VEGF Ab ([[bevacizumab]]) + atezo (NEJM 2018;378:2288)
